Corporate News

Collaboration between INMUNOTEK and IDIPAZ

July 2021

INMUNOTEK and IDIPAZ (Research Institute of the Hospital Universitario La Paz) have signed an agreement to deepen the mechanisms of action of a new anticancer vaccine developed by INMUNOTEK within the RETOS-Collaboration program with the participation of the Hospital Clínico San Carlos, Universidad Complutense de Madrid and CIB-CSIC.
More info

INMUNOTEK at EAACI 2021

July 2021

INMUNOTEK has been present at the annual EAACI congress (European Academy of Allergy and Clinical Immunology) held on July 10-12, for the first time in hybrid form between Krakow and Madrid.
More info

INMUNOTEK at SPAP Digital 2021

May 2021

INMUNOTEK has participated in the SPAP (Portuguese Society of Pediatric Allergology) Digital Congress with the presentation "Trained immunity vaccines (TIbV) through mucosa against viral infections: the MV130 model" by Dr. Laura Conejero Hall.
More info

INMUNOTEK at the XLV Congress of SEICAP

May 2021

INMUNOTEK has participated in the XLV Congress of the SEICAP (Spanish Society of Clinical Immunology, Allergology and Pediatric Asthma) in the session "Meeting with the Expert" entitled "Mite allergens and their cross-reactivity. From scientific evidence to real practice in pediatric patients".
More info

INMUNOTEK Symposium at the 42nd SEI Congress

March 2021

Within the 42nd congress of the SEI (Spanish Society of Immunology) INMUNOTEK has organized a satellite symposium on trained immunity-based vaccines (TIbV) that act through mucosa and their potential role against respiratory infections of viral origin.
More info